Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 31, 2013Molecular Cancer Therapeutics

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMaria E. ArcilaNorthside HospitalKNKhédoudja NafaMemorial Sloan Kettering Cancer CenterJCJamie E. ChaftMemorial Sloan Kettering Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Arcila et al. (2013) studied this question.

synapsesocial.com/papers/69dc31ec3080d3567e274701https://doi.org/10.1158/1535-7163.mct-12-0620
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non‐Hodgkin lymphoma2012 · 2 citations
  2. 2Predicting the functional impact of protein mutations: application to cancer genomics2011 · 2,152 citations
  3. 3Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing SomaticEGFRMutation Testing2007 · 162 citations
  4. 4Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas2012 · 507 citations
  5. 5Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors2007 · 87 citations